Failure Of Roche’s Nine-Year Alzheimer’s Prevention Study Disappointing, But No Surprise
Crenezumab Fails Again
The ambitious prevention study in people with a nearly 100% chance of developing Alzheimer’s disease has failed, and attention will now switch to trial readouts for the next generation of beta-amyloid targeting candidates.
You may also be interested in...
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.
Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab.
Another hard-to-explain result in Alzheimer’s, with AC Immune claiming the first ever validation of anti-tau therapy, but others are more circumspect.